Is Healthcare Triangle, Inc. overvalued or undervalued?

As of 23 November 2021, the valuation grade for Healthcare Triangle, Inc. moved from does not qualify to risky, indicating a significant change in its perceived investment quality. The company is currently considered overvalued, particularly given its negative financial metrics. Key ratios include a Price to Book Value of 0.31, an EV to EBIT of 0.71, and an ROE of -67.70%.
In comparison to peers, Healthcare Triangle's valuation metrics are concerning. For instance, MMTec, Inc. has a less negative EV to EBITDA of -0.2177, while NetSol Technologies, Inc. stands out with an attractive P/E ratio of 26.34. The stark contrast in performance highlights the risks associated with Healthcare Triangle, especially as it has underperformed significantly against the S&P 500, with a year-to-date return of -96.86%.